WHO proposes rescheduling cannabis to allow medical applications

@article{Mayor2019WHOPR,
  title={WHO proposes rescheduling cannabis to allow medical applications},
  author={Susan Mayor},
  journal={BMJ},
  year={2019},
  volume={364}
}
  • S. Mayor
  • Published 5 February 2019
  • Medicine
  • BMJ
The World Health Organization has proposed rescheduling cannabis within international law to take account of the growing evidence for medical applications of the drug, reversing its position held for the past 60 years that cannabis should not be used in legitimate medical practice. The WHO Expert Committee on Drug Dependence met late last year to critically review available evidence on cannabis and related substances and to agree the most appropriate level of international control.1 The… 
View on BMJ
ncbi.nlm.nih.gov
14 Citations
Background Citations
3

14 Citations

Citation Type

Citation Type

Medical Use of Cannabis in Africa: The Pharmacists’ Perspective
TLDR
Perception as pharmacists regarding the medical use of cannabis and the possible roles of pharmacists in maximizing its use in Africa are shared.
Online survey into developing a model for a legal cannabis market in the United Kingdom
TLDR
A model for a legal cannabis market in the UK building upon the results of a preceding study in which a UK population sample determined that pharmacies are the most suitable primary legal vendor of cannabis as opposed to regulated shops or the black market is developed.
Medicinal use of cannabis based products and cannabinoids
TLDR
Here, drugs perceived by policy makers to have no medical value and a high risk of misuse, such as MDMA (3,4-methylenedioxy-methamphetamine, common street name “ecstasy”) are placed in Schedule One.
WHO’s first scientific review of medicinal Cannabis: from global struggle to patient implications
TLDR
The process was historically unprecedented, of political relevance to both medical Cannabis and evidence-based scheduling generally, and the landscape resulting from accepted and rejected recommendations allow countries to continue creating decentralised, non-uniform systems for access to and availability of “Cannabis” and “cannabis resin” for medical purposes.
Controlled administration of cannabis to mitigate cannabis-attributable harm among recreational users: a quasi-experimental study in Germany.
TLDR
This study aims to reduce harm for cannabis users through legal access to herbal cannabis through pharmacies through pharmacies and may inform a regulation model for Germany and other jurisdictions and deepen the understanding of the effects of legal access.
Controlled administration of cannabis to mitigate cannabis-attributable harm among recreational users: a quasi-experimental study in Germany
TLDR
This study aims to reduce harm for cannabis users through legal access to herbal cannabis through pharmacies through pharmacies and may inform a regulation model for Germany and other jurisdictions and deepen the understanding of the effects of legalAccess to cannabis.
Medical marijuana. What can we learn from the experiences in Canada, Germany and Thailand?
Elicitation of stakeholder viewpoints about medical cannabis research for pain management in critically ill ventilated patients: A Q-methodology study
TLDR
Using a q-methodology design, the majority support medical cannabis research in critically ill patients is determined, and three factors emerged that seemed to adequately describe the relative ranking of q-statements by the majority of respondents.
Cannabidiol Adverse Effects and Toxicity.
TLDR
CBD has proven therapeutic efficacy for serious conditions such as Dravet and Lennox-Gastaut syndromes and is likely to be recommended off label by physicians for other conditions, however, AEs and potential drug-drug interactions must be taken into consideration by clinicians prior to recommending off-label CBD.
Medical cannabis for orthopaedic patients with chronic musculoskeletal pain: does evidence support its use?
TLDR
It is the position that cannabinoids may be considered as an adjunctive therapy after recommended first- and second-line therapies have failed to provide sufficient efficacy or tolerability.
...
1
2
...